Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1610-1619

  Jacob, Chaim O ^a   Guo, Shunhua ^a   Jacob, Noam ^a   Pawar, Rahul D ^b   Putterman, Chaim ^b   Quinn III, William J ^c   Cancro, Michael P ^c   Migone, Thi Sau ^d   Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; LYMPHOCYTE; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BONE MARROW CELLS; COMPLEMENT C3; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; MICE, KNOCKOUT; PLASMA CELLS; SPECIES SPECIFICITY; SPLEEN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84860456621     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33458     Document Type: Article

References (49)

1. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
2. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
3. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
4. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A,. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 1994; 22: 1147-54.
5. Von Bulow GU, Bram RJ,. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138-41.
6. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, et al. BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-11.
7. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001; 11: 1547-52.
8. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
9. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 3370-5.
10. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
11. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-91.
12. Stohl W, Jacob N, Guo S, Morel L,. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum 2010; 62: 2432-42.
13. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959-71.
14. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
15. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immuneâbased rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
16. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
17. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9.
18. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W,. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6.
19. Becker-Merok A, Nikolaisen C, Nossent HC,. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006; 15: 570-6.
20. Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R,. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131-7.
21. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 2002; 17: 515-24.
22. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524-34.
23. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724-34.
24. z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice: origins and initial characterization. Lab Invest 1993; 68: 419-26.
25. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 2006; 177: 2671-80.
26. Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, et al. B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011; 186: 4984-93.
27. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
28. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
29. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A,. Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-8.
30. Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1: 252-6.
31. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000; 275: 35478-85.
32. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192: 1677-83.
33. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-21.
34. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12: R48.
35. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005; 201: 35-9.
36. Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T,. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007; 109: 2961-7.
37. 2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Cell 2007; 26: 812-26.
38. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755-64.
39. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 2004; 101: 3903-8.
40. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009; 182: 2532-41.
41. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, Quinn WJ III, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 2008; 105: 15517-22.
42. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24: 997-1006.
43. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al, and the Merck Serono and ZymoGenetics Atacicept Study Group. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142-50.
44. Stein JV, Lopez-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109: 1587-98.
45. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34-9.
46. Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y,. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 2006; 63: 299-303.
47. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, et al. Inverse association between circulating APRIL levels and serologic and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096-103.
48. Huard B, Schneider P, Mauri D, Tschopp J, French LE,. T cell costimulation by the TNF ligand BAFF. J Immunol 2001; 167: 6225-31.
49. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-17.